nach oben

Erschienen in:

10.02.2023 | Herzinsuffizienz | CME

Herzinsuffizienz mit erhaltener Ejektionsfraktion (HFpEF)

Diagnose und Therapie

verfasst von: PD. Dr. med. Caroline Morbach, Prof. Dr. med. Stefan Störk, PhD

Erschienen in: Herz | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Zusammenfassung

Herzinsuffizienz mit erhaltener Ejektionsfraktion („heart failure with preserved ejection fraction“, HFpEF) ist verantwortlich für rund die Hälfte aller herzinsuffizienzassoziierten Krankenhausaufenthalte. Die Prävalenz von HFpEF nimmt zu, v. a. aufgrund einer alternden Bevölkerung und einer zunehmenden Belastung durch Begleiterkrankungen wie Bluthochdruck, Diabetes, Adipositas. Trotz verstärkter Forschungsanstrengungen bestehen nach wie vor relevante Lücken im Hinblick auf das pathophysiologische Verständnis von HFpEF und die praxisbezogene Diagnostik. Da HFpEF auch auf seltene Herzerkrankungen zurückzuführen sein kann, ist es wichtig, um die Möglichkeit zu wissen, Patienten bei unklaren Konstellationen in spezialisierten Zentren zur Diagnostik und Therapieinitiierung vorzustellen. Erst seit Kurzem gibt es therapeutische Ansätze, die harte klinische Endpunkte nachweislich bei Patienten mit HFpEF beeinflussten und jetzt in die Routineversorgung implementiert werden müssen.

Bozkurt B, Coats AJS, Tsutsui H et al (2021) Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 23(3):352–380. https://doi.org/10.1002/ejhf.2115CrossRefPubMed

van Riet EE, Hoes AW, Wagenaar KP et al (2016) Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail 18(3):242–252. https://doi.org/10.1002/ejhf.483CrossRefPubMed

Schulz A, Schuster A (2022) Visualizing diastolic failure: non-invasive imaging-biomarkers in patients with heart failure with preserved ejection fraction. eBioMedicine 86:104369. https://doi.org/10.1016/j.ebiom.2022.104369CrossRefPubMedPubMedCentral

Owan TE, Hodge DO, Herges RM et al (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355(3):251–259. https://doi.org/10.1056/NEJMoa052256CrossRefPubMed

Tsao CW, Lyass A, Enserro D et al (2018) Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail 6(8):678–685. https://doi.org/10.1016/j.jchf.2018.03.006CrossRefPubMedPubMedCentral

McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599–3726. https://doi.org/10.1093/eurheartj/ehab368CrossRefPubMed

Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145(18):e895–e1032. https://doi.org/10.1161/CIR.0000000000001063CrossRefPubMed

Hellenkamp K, von Haehling S (2019) The relevance of biomarkers in acute heart failure. Internist 60(6):587–596. https://doi.org/10.1007/s00108-019-0606-7CrossRefPubMed

Reddy YNV, Carter RE, Obokata M et al (2018) A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 138(9):861–870. https://doi.org/10.1161/CIRCULATIONAHA.118.034646CrossRefPubMedPubMedCentral

10.

Pieske B, Tschope C, de Boer RA et al (2019) How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 40(40):3297–3317. https://doi.org/10.1093/eurheartj/ehz641CrossRefPubMed

11.

Lofstrom U, Hage C, Savarese G et al (2019) Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction. ESC Heart Fail 6(4):830–839. https://doi.org/10.1002/ehf2.12458CrossRefPubMedPubMedCentral

12.

McKee PA, Castelli WP, McNamara PM et al (1971) The natural history of congestive heart failure: the Framingham study. N Engl J Med 285(26):1441–1446. https://doi.org/10.1056/NEJM197112232852601CrossRefPubMed

13.

Vaishnav J, Sharma K (2022) A stepwise guide to the diagnosis and treatment of heart failure with preserved ejection fraction. J Card Fail 28(6):1016–1030. https://doi.org/10.1016/j.cardfail.2021.12.013CrossRefPubMed

14.

Churchill TW, Li SX, Curreri L et al (2021) Evaluation of 2 existing diagnostic scores for heart failure with preserved ejection fraction against a comprehensively phenotyped cohort. Circulation 143(3):289–291. https://doi.org/10.1161/CIRCULATIONAHA.120.050757CrossRefPubMedPubMedCentral

15.

Backhaus SJ, Lange T, George EF et al (2021) Exercise stress real-time cardiac magnetic resonance imaging for noninvasive characterization of heart failure with preserved ejection fraction: the HFpEF-stress trial. Circulation 143(15):1484–1498. https://doi.org/10.1161/CIRCULATIONAHA.120.051542CrossRefPubMed

16.

Olivotto I, Oreziak A, Barriales-Villa R et al (2020) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 396(10253):759–769. https://doi.org/10.1016/S0140-6736(20)31792-XCrossRefPubMed

17.

Murphree CR, Nguyen NN, Raghunathan V et al (2020) Diagnosis and management of hereditary haemochromatosis. Vox Sang 115(4):255–262. https://doi.org/10.1111/vox.12896CrossRefPubMed

18.

Pieroni M, Moon JC, Arbustini E et al (2021) Cardiac involvement in Fabry disease: JACC review topic of the week. J Am Coll Cardiol 77(7):922–936. https://doi.org/10.1016/j.jacc.2020.12.024CrossRefPubMed

19.

Yilmaz A, Bauersachs J, Bengel F et al (2021) Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol 110(4):479–506. https://doi.org/10.1007/s00392-020-01799-3CrossRefPubMedPubMedCentral

20.

Wechalekar AD, Fontana M, Quarta C et al (2022) AL amyloidosis for cardiologists. Jacc Cardio Oncol 4(4):427–441. https://doi.org/10.1016/j.jaccao.2022.08.009CrossRef

21.

Kitzman DW, Upadhya B, Reeves G (2015) Hospitalizations and prognosis in elderly patients with heart failure and preserved ejection fraction: time to treat the whole patient. JACC Heart Fail 3(6):442–444. https://doi.org/10.1016/j.jchf.2015.01.009CrossRefPubMedPubMedCentral

22.

Pandey A, Parashar A, Kumbhani D et al (2015) Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail 8(1):33–40. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001615CrossRefPubMed

23.

Kitzman DW, Whellan DJ, Duncan P et al (2021) Physical rehabilitation for older patients hospitalized for heart failure. N Engl J Med 385(3):203–216. https://doi.org/10.1056/NEJMoa2026141CrossRefPubMedPubMedCentral

24.

Abraham WT, Adamson PB, Bourge RC et al (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 377(9766):658–666. https://doi.org/10.1016/S0140-6736(11)60101-3CrossRefPubMed

25.

Angermann CE, Assmus B, Anker SD et al (2020) Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). Eur J Heart Fail 22(10):1891–1901. https://doi.org/10.1002/ejhf.1943CrossRefPubMed

26.

Prandi FR, Barone L, Lecis D et al (2022) Biomolecular mechanisms of cardiorenal protection with sodium-glucose co-transporter 2 inhibitors. Biomolecules. https://doi.org/10.3390/biom12101349CrossRefPubMedPubMedCentral

27.

Anker SD, Butler J, Packer M (2022) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 386(21):e57. https://doi.org/10.1056/NEJMc2118470 (Reply)CrossRefPubMed

28.

Solomon SD, McMurray JJV, Claggett B et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387(12):1089–1098. https://doi.org/10.1056/NEJMoa2206286CrossRefPubMed

29.

Vaduganathan M, Docherty KF, Claggett BL et al (2022) SGLT‑2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 400(10354):757–767. https://doi.org/10.1016/S0140-6736(22)01429-5CrossRefPubMed

30.

Heerspink HJL, Stefansson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436–1446. https://doi.org/10.1056/NEJMoa2024816CrossRefPubMed

31.

Group E‑KC, Herrington WG, Staplin N et al (2022) Empagliflozin in patients with chronic kidney disease. N Engl J Med. https://doi.org/10.1056/NEJMoa2204233CrossRef

32.

Heerspink HJL, Jongs N, Chertow GM et al (2021) Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9(11):743–754. https://doi.org/10.1016/S2213-8587(21)00242-4CrossRefPubMed

33.

Talha KM, Butler J, Greene SJ et al (2022) Population-level implications of sodium-glucose cotransporter‑2 inhibitors for heart failure with preserved ejection fraction in the US. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2022.4348CrossRef

Titel: Herzinsuffizienz mit erhaltener Ejektionsfraktion (HFpEF)
Diagnose und Therapie
verfasst von: PD. Dr. med. Caroline Morbach
Prof. Dr. med. Stefan Störk, PhD
Publikationsdatum: 10.02.2023
Verlag: Springer Medizin
Schlagwörter: Herzinsuffizienz
Herzerkrankungen und Komorbidität
Diagnostik in der Kardiologie
Diagnostik in der Kardiologie
Erschienen in: Herz / Ausgabe 2/2023
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-022-05156-0

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Current status of antithrombotic therapy and in-hospital outcomes in patients with atrial fibrillation undergoing percutaneous coronary intervention in Germany

Akute Herzinsuffizienz und kardiogener Schock

Impact of residual coronary artery disease on left ventricular function after percutaneous coronary intervention: a two-dimensional strain echocardiography study

How arrhythmias weaken the ventricle: an often underestimated vicious cycle

Europäische Leitlinien Herzinsuffizienz: medikamentöse Therapie

Mechanoenergetische Defekte bei Herzinsuffizienz